Zydus Lifesciences Limited (Zydus) is a multinational pharmaceutical company based in India. It specializes in the development and manufacturing of generic medicines. It was ranked 100th on the Fortune India 500 list for 2020. The company was previously known as Cadila Healthcare Limited.
NSE: Zydus Lifesciences Limited
NSE: Zydus Lifesciences Limited is a multinational pharmaceutical company based in India. It manufactures generic drugs and ranks 100th in the 2020 Fortune India 500 list. It was formerly known as Cadila Healthcare Limited. The company has over 4,000 employees, and its products treat various ailments.
The company has several manufacturing facilities in India, the US, and Brazil. It also has a presence in Kenya, Uganda, Sri Lanka, the Philippines, and Japan. The company has several joint venture agreements around the world. Among these are Anda Biologicals, which will appoint a maximum of two distributors in India.
The company manufactures a range of products, including Active Pharmaceutical Ingredients (APIs), human formulations, animal health products, and consumer wellness products. Its product lines include Complan, Nycil, Levoday, Metascore, and Aten. The company also offers a range of speciality products.
The company acquired two subsidiaries in South Africa. NSE: Zydus Pharmaceuticals Limited is a wholly-owned subsidiary of the company, while Zoom Properties Limited is a joint venture with Germany. It also launched a new bulk drug manufacturing project in Ankleshwar and started a feed supplement plant in Vatwa. In addition, it has set up a joint venture to manufacture Pantoprazole. The company also undertakes discovery research projects with Byk Gulden.
Merck’s portfolio is focused on generics, animal health, and pain management, but the company also produces various herbal and OTC products. In India, the company launched Falcigo, a vaccine that combats malaria, and the company formed a joint venture in the same region with Cherry Valley Farms Ltd.
NSE: Zydus Lifesciences Limited (Zydus) is an Indian multinational pharmaceutical company primarily manufacturing generic drugs. The company is ranked 100th on the Fortune India 500 list for 2020. NSE: Zydus Lifesciences Limited was formerly known as Cadila Healthcare Limited.
The company was founded in 1952 and is based in Ahmedabad, India. It has a large pipeline and manufactures various pharmaceutical products. Its products include active pharmaceutical ingredients, human formulations, animal health & veterinary products, and cosmeceuticals. The company was founded in 1952 by Ramanbhai B. Patel, a member of the Indian Parliament.
NSE: Zydus is committed to the health and wellness of human beings and is dedicated to advancing science. Its CSR program, Zydus Srishti, focuses on education, research, and outreach. The company has also formed meaningful partnerships with the community.
The company grew significantly in its second quarter. Its operations were further expanded as Zydus Cadila and Indon Healthcare Limited became wholly-owned subsidiaries of Zydus Life. In addition, the company established a new bulk drug manufacturing facility in Ankleshwar. It also laid the foundation for a new feed supplement plant in Vatwa. It also entered into a joint venture with Korea Green Cross Corporation.
Zydus Cadila has entered a technical collaboration with Ethical Holdings in the UK, where Ethical Holdings manufactures transdermal patches. The company also announced the acquisition of Rs 54 crore Recon Limited, which acquired its formulation brands and distribution network. Cadila has plans to acquire more overseas companies.
There’s a lot of uncertainty in the US pharmaceutical sector, and Zydus Lifesciences’ prospects for the US segment remain uncertain. The company has already reduced its pipeline size from 35 to 20 in FY22, and it remains to be seen whether the US FDA will clear the Moraiya plant. The company has been dealing with regulatory action at the site for over 6 years and is still awaiting the final inspection. If the plant’s FDA clearance is delayed, it will be difficult for Zydus Lifesciences to make money from its pipeline. Moreover, their products will have to be priced accordingly, which means that their value will be reduced.
Zydus Lifesciences has three main business divisions. The largest is pharmaceuticals, followed by medical equipment and medical education. In addition, the company provides consulting services to other companies in India, including regulatory assistance, drug registration services, and strategic marketing support. Its flagship company, Cadila Healthcare Ltd, is a global leader in the medical field.
Zydus has invested heavily in research and development, employing more than 1300 scientists at 19 facilities worldwide. These researchers are focused on developing unique medicines for the future. Its pipeline includes NCEs, vaccines, biosimilars, and specialized technologies. The company is constantly innovating and has recently gained approval from the Drug Controller General of India for human trials of the COVID-19 vaccine.
The company also acquired Sentynl Therapeutics Inc., a speciality pharmaceutical company, and entered into an exclusive licensing agreement with Pharm Aid Ltd. It also licensed poultry vaccine technologies from Phibro Animal Health Corporation. And it has also built a new vaccine manufacturing facility in India. Moreover, the company has recently received a Nod from the US Food and Drug Administration (FDA) for a sedative injection.
Zydus Lifesciences Limited, formerly Cadila Healthcare Limited, is a large pharmaceutical company in India. It is focused on manufacturing generic drugs. The company is ranked 100th on the Fortune India 500 list. Its shares are valued at about $1 billion and are traded on the NASDAQ stock market.
If you want to invest in Zydus Life Science, you can sign up for a Demat account and begin trading on the stock. Alternatively, you can use ETPrime to track Zydus Life Science’s stock. Buying Zydus shares through these services will require you to complete KYC documents online.
The revenue of Zydus Lifesciences Ltd. rose by 10% to Rs 41,347 million in the last fiscal year. Its R&D investments totalled about Rs 2,534 million. The company also provides consulting services to other companies in India, including drug registration, regulatory assistance, and strategic marketing support.
ZYDUS LIFE traded in a downtrend from July 2021 to May 2022. After that, it stopped making lower lows and has been in a sideways accumulation phase for the past three months. Recently, it broke out of its sideways pattern and started moving higher. If this pattern continues, ZYDUS LIFE could hit 400.
The insiders at Zydus Lifesciences Limited hold almost 75% of the company’s stock. This means that they stand to benefit the most if the stock increases and have the most to lose if the stock decreases. This also means they are incentivized to make good decisions for the company.
In the last year, Zydus Lifesciences Ltd. reported revenues of Rs 41,347 million, up 10% from the previous year. Its research and development expenditures totalled Rs 2,534 million. It is one of the leading pharmaceutical companies in India, with products in various categories and segments.